Seelos Therapeutics Inc (SEEL)
0.3365
-0.05
(-12.61%)
USD |
NASDAQ |
Apr 17, 16:00
0.3515
+0.01
(+4.45%)
After-Hours: 20:00
Seelos Therapeutics Cash from Financing (TTM): 11.38M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 11.38M |
September 30, 2023 | 7.164M |
June 30, 2023 | 5.008M |
March 31, 2023 | 7.194M |
December 31, 2022 | -1.597M |
September 30, 2022 | 20.53M |
June 30, 2022 | 20.34M |
March 31, 2022 | 77.87M |
December 31, 2021 | 112.07M |
September 30, 2021 | 102.76M |
June 30, 2021 | 109.00M |
March 31, 2021 | 51.74M |
December 31, 2020 | 26.31M |
September 30, 2020 | 15.44M |
June 30, 2020 | 17.56M |
March 31, 2020 | 19.18M |
December 31, 2019 | 29.52M |
September 30, 2019 | 33.57M |
June 30, 2019 | 21.97M |
March 31, 2019 | 23.29M |
December 31, 2018 | 5.377M |
September 30, 2018 | 1.397M |
June 30, 2018 | 7.925M |
March 31, 2018 | 10.90M |
December 31, 2017 | 2.501M |
Date | Value |
---|---|
September 30, 2017 | 1.544M |
June 30, 2017 | 1.876M |
March 31, 2017 | -5.317M |
December 31, 2016 | 11.00M |
September 30, 2016 | 11.33M |
June 30, 2016 | 12.58M |
March 31, 2016 | 13.59M |
December 31, 2015 | 15.45M |
September 30, 2015 | 20.44M |
June 30, 2015 | 18.27M |
March 31, 2015 | 17.33M |
December 31, 2014 | 7.865M |
September 30, 2014 | 3.384M |
June 30, 2014 | 0.54M |
March 31, 2014 | 17.42M |
December 31, 2013 | 16.63M |
September 30, 2013 | 17.85M |
June 30, 2013 | 17.87M |
March 31, 2013 | 2.023M |
December 31, 2012 | 20.77M |
September 30, 2012 | 19.97M |
June 30, 2012 | 22.52M |
March 31, 2012 | 23.73M |
December 31, 2011 | 7.666M |
September 30, 2011 | 16.64M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-1.597M
Minimum
Dec 2022
112.07M
Maximum
Dec 2021
36.16M
Average
20.53M
Median
Sep 2022
Cash from Financing (TTM) Benchmarks
180 Life Sciences Corp | 5.908M |
Acurx Pharmaceuticals Inc | -- |
NovaBay Pharmaceuticals Inc | 1.91M |
Palatin Technologies Inc | 5.553M |
iBio Inc | 10.68M |